NTLA Intellia Therapeutics, Inc.
FY2025 10-K
Intellia Therapeutics, Inc. (NTLA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: biotechnology firm developing CRISPR-based in vivo genome editing therapies targeting severe diseases
- • New emphasis on Phase 3 products lonvo-z and nex-z for hereditary angioedema and transthyretin amyloidosis, with commercial launch preparation for lonvo-z in H1 2027
Management Discussion & Analysis
- • No revenue or profitability data provided for fiscal year 2026
- • No segment performance or cash flow details disclosed
Risk Factors
- • Regulatory risk: potential impact of SEC scrutiny on forward-looking statements disclosed in 2026 10-K
- • Geopolitical/macroeconomic risk: $117.7M common stock shares remain under the amended 2022 Sale Agreement with Jefferies exposure to market volatility
Get deeper insights on Intellia Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.